Navigation Links
DrugRisks Legal Update: Jury to Decide Actos Cancer Trial This Week

New York, NY (PRWEB) April 18, 2013

The drug safety advocates at are alerting of updated legal news on the site for patients who have taken the diabetes drug Actos. A jury could begin deliberations today in a trial accusing Takeda Pharmaceuticals of causing bladder cancer with their diabetes drug Actos***.

DrugRisks is designed to improve the safety of those taking popular prescription drugs like Actos by providing the latest warnings, recalls, studies and legal news. Visitors can determine if other patients are experiencing similar side effects and decide if they need legal advice.

The FDA and European Medicines Agency* have warned that taking Actos for longer than one year may be associated with an increased risk of bladder cancer. Regulators in France and Germany have even banned its use**.

DrugRisks has learned as many as 3,000 patients in the U.S. have filed an Actos lawsuit against Takeda Pharmaceuticals over allegations their drug caused bladder cancer***. The first trial is underway for Jack Cooper, a grandfather who is now terminally ill from the disease***.

Now, the resource center has added legal news showing lawyers are finishing their closing arguments and the jury could begin deliberations as soon as Tuesday or Wednesday this week. A decision is expected soon***.

Lawyers continue to help those diagnosed with bladder cancer after taking Actos file claims. Anyone affected is urged to contact the DrugRisks Center or speak with a lawyer about their legal rights as soon as possible.

Due to the specialized nature of drug injury litigation against large pharmaceutical companies, DrugRisks only recommends lawyers and law firms who have already handled Actos lawsuits.

Visit today for more information on Actos bladder cancer research, side effects and litigation news, or to speak with a lawyer.

*; an_pha_detail_000033.jsp&mid=WC0b01ac058001d126

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisks Update: Doctor Testifies Actos Main Cause of Bladder Cancer in Trial
2. DrugRisks Adds Study Showing Pradaxa Viral Infection Risk
3. DrugRisks Stryker Recall Update: Company Warns Investors as Patients Alleging Injury Ask to Send Lawsuits to Federal Court
4. DrugRisks Center NuvaRing Lawsuit News: Drug Maker May Have Concealed Risks
5. DrugRisks Adds New Pradaxa Study Alert As Lawsuits Increase
6. DrugRisks Adds Update from First Actos Trial of Patient Alleging Bladder Cancer
7. Nia Vardalos Speaks Out on Adoption, Bolsters Legal Support for Abused Children
8. Tariq Drabu Supports Latest Campaign Against Illegal Tooth Whitening
9. Best Injury Lawyers? Time Magazine Includes Among Nations Legal Leaders
10. Gun retailers take a hard line on illegal firearm sales, UC Davis survey finds
11. Yasmin Blood-Clotting Lawsuits Update: Resource4thePeople Providing Legal Assistance as Concerns Rise Over Health Risks
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... Purdue University announced Tuesday (Oct. ... Initiative aimed at enhancing Purdue’s life sciences research and graduate education. The initiative ... , The investment will result in cohesive efforts across several colleges and is ...
(Date:10/13/2015)... ... 13, 2015 , ... "My friend's son suffers from eczema, and he had ... an inventor from Platteville, Colo. "I came up with this kit as a way ... to prevent a child from rubbing or scratching his or her face. This protects ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ProText Kinetic ... X . With ProText Kinetic Panel, users can create energetic text animations in any ... preset into the Final Cut Pro X timeline and stylize the text. With intuitive ...
(Date:10/13/2015)... ... October 13, 2015 , ... Relay (, a technology ... today a significant contract that will provide its award-winning private messaging solution to ... the growing success of its Relay program, IBX Wire™, which now has over ...
(Date:10/13/2015)... ... October 13, 2015 , ... Leading Internet marketing product review ... "Publish Academy" training course . Singal's new program, in which he reveals his ... around the Internet are weighing in with reviews. , "Considering the fairly high ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... 2015  Nanomedical Diagnostics, a biotech company developing ... diagnostics, announces the completion of a Series A ... Ventures. --> ... monitoring and diagnostic platforms that empower individuals to ... will enable the company to commercially release AGILE ...
(Date:10/13/2015)... Oct. 9, 2015 Research and Markets ( ... "Kombucha Market by Types (Bacteria, Yeast, Mold, Others), Flavors ... Flowers, Others), & by Region - Forecasts to 2020" ... --> --> The global ... few years. In terms of value, the market is ...
(Date:10/13/2015)... Oct. 13, 2015   Micell Technologies , Inc. ... and II trials of its MiStent Sirolimus Eluting Absorbable ... ) were presented at the 27th Annual Transcatheter Cardiovascular ... San Francisco , October 11-15. TCT is the ... MiStent SES was designed to optimize vessel healing in ...
Breaking Medicine Technology: